Related Experiment Video
Updated: Jul 20, 2026
08:27
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
[Pharmacotherapy for Alzheimer's disease]
1Neuropsychiatrie en Ouderenpsychiatrie verbonden aan het Academisch Ziekenhuis Maastricht en de Universiteit Maastricht. F.verhey@np.unimaas.nl
Tijdschrift Voor Psychiatrie
|September 8, 2006
Summary
Current Alzheimer's disease treatments like cholinesterase-inhibitors and memantine offer limited benefits for cognition and daily function, often with frequent side effects. A comprehensive approach integrating these drugs with psychosocial interventions is recommended.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- No causal therapies exist for Alzheimer's disease (AD).
- Four drugs are licensed for symptomatic treatment: donepezil, rivastigmine, galantamine, and memantine.
Purpose of the Study:
- To systematically review the efficacy and side effects of licensed Alzheimer's disease drugs.
- Evaluate the clinical utility of cholinesterase-inhibitors and memantine.
Main Methods:
- Systematic literature search using PubMed, MEDLINE, and the Cochrane Library.
- Review focused on efficacy and adverse events of AD symptomatic treatments.
Main Results:
- Cholinesterase-inhibitors and memantine demonstrate a beneficial effect on cognition and daily functioning in Alzheimer's patients.
- The observed benefits are limited in scope.
- Cholinesterase-inhibitors are frequently associated with side effects.
Conclusions:
- Treatment for Alzheimer's disease requires a careful and realistic strategy.
- These medications should be used adjunctively with psychosocial interventions.
- Integrated care plans are essential for optimal Alzheimer's patient management.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...